Here are six points:
1. The market will continue to grow at a compound annual growth rate of 5.7 percent.
2. Current TAR products are designed to reduce tibial and talar bone resection to foster implant stability.
3. Long-term viability trials and positive study outcomes have reactivated the interest in the TAR market.
4. Germany accounted for 38 percent of the regional market revenue, and will likely maintain this dominance through 2023.
5. The Czech Republic, Hungary and the Netherlands will each grow at a 7.6 percent CAGR, representing the most rapidly growing markets.
6. Kalamazoo, Mich.-based Stryker; Plainsboro, N.J.-based Integra LifeSciences; Memphis, Tenn.-based Wright Medical; Warsaw, Ind.-based DePuy Synthes; and Warsaw, Ind.-based Zimmer Biomet lead the space.
More articles on devices:
15 things to know about cervical artificial disc replacement
Mazor X now utilized in 5 hospitals worldwide — 4 key notes
Nemours Children’s Health System buys 3rd EOS imagine device — 5 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
